FOLH1 and prostate carcinoma: The potential role of PSMA ligands in this clinical setting is for in vivo evaluation of PSMA expression and, subsequently, assessment of potential indications to targeted radionuclide therapy using PSMA ligands labeled with beta-emitters (177Lu) or, in the future, also alpha-emitters (e.g., 225Ac) as it is already the case in the treatment of prostate cancer [27].